Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
Globe Newswire•16/11/2026•03:30 ET
1
Key Highlights
- ➤Aclaris (ACRS) initiates Phase 2b ALPHA trial of modzatinib in moderate-to-severe lichen planus
- ➤Approximately 100 participants will receive two modzatinib doses or placebo
- ➤FDA grants Fast Track Designation for modzatinib in moderate-to-severe lichen planus
- ➤Topline results from the oral erosive lichen planus cohort expected in the second half of 2027
- ➤Aclaris expects to file ATI-9494’s IND this quarter and start Phase 1 in Q1 2027
Expert Statements
Jesse Hall, Chief Medical Officer of Aclaris Therapeutics
“We are excited to initiate the ALPHA trial, particularly given the unmet medical need in lichen planus and the mechanistic potential for modzatinib in this indication.”
Jesse Hall, Chief Medical Officer of Aclaris Therapeutics
“Modzatinib has demonstrated activity in multiple non-clinical disease models, including severe alopecia areata, vitiligo, and rheumatoid arthritis, as well as in a Phase 2a trial in atopic dermatitis with rapid and sustained improvements across clinical and patient-reported measures of disease severity, pruritus, and quality of life.”
Jesse Hall, Chief Medical Officer of Aclaris Therapeutics
“This provides support for its continued development across immuno-inflammatory diseases.”
Jesse Hall, Chief Medical Officer of Aclaris Therapeutics
“There are no FDA-approved therapies for people living with this debilitating disease, and we believe that modzatinib has the potential to be the first mechanistically complete oral therapy in this setting.”
- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -
- Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream -
Get started
Create a free account to read the full story.
